Drugs / C11-Choline
C11-Choline
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01051479 | Mar 2010 → Aug 2013 | esophageal cancer | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02397408 | Apr → Jun 2015 | prostate cancer | University of California, San Francisco | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02852122 | Jan 2015 → Dec 2016 | prostate cancer | Chang Gung Memorial Hospital | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C11-Choline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01051479 ↗ |
| Known as | 11C-choline | “15 mCi 11C-choline will be administered intravenously as a bolus.” NCT01051479 ↗ |
| Known as | Carbon C 11 Choline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02397408 ↗ |
| Modality | Diagnostic / imaging agent | “11C-Choline PET-CT images” NCT01051479 ↗ |
| Route | Intravenous | “administered intravenously” NCT01051479 ↗ |